HealthEquity: Attractive Given Improved Cash Economics (Rating Upgrade)

HealthEquity upgraded to buy with ~25% one-year upside; shares trade at ~17x forward earnings. EPS expected to grow ~15% in FY27 and at least 10% in calendar 2027 driven by repricing of cash yields; secular HSA account growth, an improved legislative environment, and rising custodial yields underpin earnings visibility and margin expansion.

Analysis

HealthEquity’s story is less about HSA unit growth and more about how custodial float monetization scales through operating leverage. As custodial yields rise, a modest increment in average cash yield translates non-linearly into EPS because incremental custodial income drops almost straight to the pre-tax line while platform costs are largely fixed; expect a visible uptick within two to four fiscal quarters as sweep re-pricings flow through.

Second-order winners include short-duration money market and treasury-fund managers that provide sweep vehicles (they will see accelerated AUM inflows), and payroll/benefits platforms that can bundle HSAs to capture cross-sell economics; conversely, admin-only providers that lack custody rails (think mid-cap benefits administrators) face margin compression or will need to sell or partner. Also watch regional banks and community custodians: if HealthEquity consolidates custody at scale, their deposits/low-cost float could shrink, tightening credit supply in local markets over years.

Principal risks are macro and political: a sustained decline in short-term yields or a Fed pivot would compress the newly realized lift, and congressional gridlock or a shift in tax policy could derail legislative tailwinds — both can reverse margins quickly. Execution risks include poorer-than-expected reinvestment of float, competitive fee discounting to win large employer conversions, and regulatory scrutiny on sweep transparency; each can shave several points off forward EPS within 6–12 months.

Actionable monitoring: track custodial yield spread vs 3M T-bill (watch for >75–100bps sustained), employer conversion cadence and churn, and any bill numbers or committee timelines in the next 6–18 months — these are leading indicators that will change valuation multiple momentum.

Key Decisions for Investors

• Long HQY (size 2–4% of portfolio) — buy into weakness over the next 3 months to capture custodial-yield repricing; set tactical stop at 15% below entry and hedge with 1–2% notional 9–12 month puts if legislative progress stalls. Risk/Reward: asymmetric — limited downside with a defined stop; objective 20–30% upside in 12 months if yields and legislative catalysts materialize.
• Options spread to express convexity — buy a 9–12 month call spread (buy 0–10% OTM, sell 25–30% OTM) to capture upside from yield re-pricing and legislative tailwinds while capping premium. Risk/Reward: defined max loss = premium; target 2–4x return if custodial yields and account momentum accelerate in 6–12 months.
• Pair trade: long HQY / short ALIT (Alight) equal notional — 12 month horizon to express preference for custody-driven margin expansion over admin-only value capture. Risk/Reward: reduces market beta; profitable if custody monetization widens relative margins by 200–300bps.
• Event hedge: if Fed signals easing within 3 months, reduce gross exposure and buy protection (puts) on HQY or sell the call spread — Fed pivot is the highest-probability near-term catalyst to reverse the thesis.